Importantly, here, we have demonstrated that drugs already in clinical use can be used to indirectly target SAMHD1 activity towards ara‐CTP and thereby possibly overcome this barrier to ara‐C efficacy in AML treatment. Here, SAMHD1 is linked to acute myeloid leukemia.